ViiV Healthcare’s investigational broadly neutralising antibody – N6LS – successfully maintains viral suppression in long-acting treatment of HIV

FHS
March 13, 2025
10:18 am

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

Study finds disruptions in functional brain connectivity in people with schizophrenia

Schizophrenia, a neurodevelopmental disorder that features psychosis among its symptoms, is thought to arise from disorganization in brain connectivity and functional integration.

October 17, 2023

Psychedelic Retreats Market Set to Cross $1 Trillion By 2027 | Psychedelic Invest

The market for psychedelic retreats is on a remarkable trajectory, with projections indicating it will surpass the $1 trillion mark by 2027. This anticipated milestone

June 14, 2024

Signal: Wave of layoffs in medical start-ups exposes underlying vulnerability – Pharmaceutical Technology

Babylon Health has shuttered operations in the US, laying off 94. Credit: Babylon Health. On 7 August, artificial intelligence (AI)-powered digital health company Babylon Health

August 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.